Psychiatric and developmental conditions in 22q11.2 deletion syndrome (22q11.2DS) are common, yet clinicians have had no reliable blood test to flag who is at risk or to track disease over time. In a study our Dalton Bioanalytics scientists co-authored with the UC Davis MIND Institute, we asked a direct question: can untargeted metabolomics and proteomics read coordinated molecular changes in plasma that single-layer tests miss? Profiling proteins and metabolites together tur

Genetic cardiomyopathy can hide in plain sight. A carrier of the phospholamban (PLN) p.Arg14del variant, written R14del, may look healthy on an echocardiogram for years, then slide into end-stage heart failure with little warning. Clinical proteomics offers a way to read that hidden trajectory from a single tube of plasma. A study in Cardiovascular Research profiled 87 R14del carriers across the disease spectrum, pairing targeted plasma proteomics with metabolomics and lipido

Low-dose CT scans pick up lung nodules that mostly turn out to be benign, and the false alarms drive biopsies, anxiety, and cost. A blood test that flags real malignancy would help decide who needs follow-up and who can be reassured. This is where proteomics earns its place. A group from Oxford Cancer Analytics and academic partners measured plasma proteins in 490 lung cancer patients and 124 matched controls, then used explainable machine learning to pull out a protein signa

Immune checkpoint blockade rescues only a sliver of colorectal cancer patients, the roughly 15 percent whose tumors are microsatellite instability-high or mismatch-repair-deficient. The microsatellite-stable majority mostly resists. A study in Molecular Therapy: Nucleic Acids applied multi-omics integration to the TCGA colorectal adenocarcinoma cohort to test whether that binary overlooks immune-hot tumors hiding inside the stable group. Pulling together messenger RNA, long n

HbA1c misleads more often than most clinicians like to admit. Iron deficiency, hemoglobinopathies, and high triglycerides all distort it, so the patient whose kidneys are quietly failing can slip past a single lab value. A recent biomarker discovery study in Frontiers in Endocrinology went hunting for a blood signal that warns earlier, mining plasma proteomics and metabolomics from 50,021 UK Biobank participants to find markers that flag type 2 diabetes complications years be